Ajinomoto Co. Inc. reported the completion of a previously announced acquisition of Althea Technologies.
Ajinomoto Co. Inc. reported the completion of a previously announced acquisition of Althea Technologies, a provider of biopharmaceutical development and manufacturing services.
According to a company statement, Ajinomoto acquired all the capital stock of Althea for a purchase price of approximately $175 million. Althea will become a fully consolidated subsidiary of Ajinomoto Co., Inc. operating under the company name Ajinomoto Althea, Inc.
Ajinomoto Co. is a global manufacturer of seasonings, processed foods, beverages, amino acids, pharmaceuticals, and specialty chemicals. Althea Technologies is a contract development and manufacturing organization located in San Diego, providing clinical and commercial product development services.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.